BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 33025309)

  • 1. Dutch translation and linguistic validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™).
    Veldhuijzen E; Walraven I; Mitchell SA; Moore EY; McKown SM; Lauritzen M; Kim KJ; Belderbos JSA; Aaronson NK
    J Patient Rep Outcomes; 2020 Oct; 4(1):81. PubMed ID: 33025309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linguistic validation of the simplified Chinese version of the US National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).
    Kkf C; Mitchell SA; Chan N; Ang E; Tam W; Kanesvaran R
    BMC Cancer; 2020 Nov; 20(1):1153. PubMed ID: 33243173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Danish Translation and Linguistic Validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Bæksted C; Nissen A; Pappot H; Bidstrup PE; Mitchell SA; Basch E; Dalton SO; Johansen C
    J Pain Symptom Manage; 2016 Aug; 52(2):292-7. PubMed ID: 27090851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linguistic validation of the Spanish version of the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Arnold B; Mitchell SA; Lent L; Mendoza TR; Rogak LJ; Barragán NM; Willis G; Medina M; Lechner S; Penedo FJ; Harness JK; Basch EM;
    Support Care Cancer; 2016 Jul; 24(7):2843-51. PubMed ID: 26838022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linguistic Validation of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Korean.
    Cho J; Yoon J; Kim Y; Oh D; Kim SJ; Ahn J; Suh GY; Nam SJ; Mitchell SA
    J Glob Oncol; 2019 Mar; 5():1-10. PubMed ID: 30917069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reliability and Validity of the Korean Language Version of the U.S. National Cancer Institute's Patient-Reported Outcomes Common Terminology Criteria for Adverse Events.
    Yoon J; Sim SH; Kang D; Han G; Kim Y; Ahn J; Oh D; Lee ES; Kong SY; Cho J; Mitchell SA
    J Pain Symptom Manage; 2020 May; 59(5):1082-1088.e6. PubMed ID: 32044423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®).
    Caminiti C; Bryce J; Riva S; Ng D; Diodati F; Iezzi E; Sparavigna L; Novello S; Porta C; Del Mastro L; Procopio G; Cinieri S; Falzetta A; Calabrò F; Lorusso V; Cogoni AA; Tortora G; Maruzzo M; Passalacqua R; Cognetti F; Adamo V; Capelletto E; Ferrari A; Bagnalasta M; Bassi M; Nicelli A; De Persis D; D'Acunti A; Iannelli Patient E; Perrone F; Mitchell SA
    Tumori; 2023 Jun; 109(3):324-334. PubMed ID: 35674125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Japanese translation and linguistic validation of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Miyaji T; Iioka Y; Kuroda Y; Yamamoto D; Iwase S; Goto Y; Tsuboi M; Odagiri H; Tsubota Y; Kawaguchi T; Sakata N; Basch E; Yamaguchi T
    J Patient Rep Outcomes; 2017; 1(1):8. PubMed ID: 29757296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Hay JL; Atkinson TM; Reeve BB; Mitchell SA; Mendoza TR; Willis G; Minasian LM; Clauser SB; Denicoff A; O'Mara A; Chen A; Bennett AV; Paul DB; Gagne J; Rogak L; Sit L; Viswanath V; Schrag D; Basch E;
    Qual Life Res; 2014 Feb; 23(1):257-69. PubMed ID: 23868457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Swahili translation and cultural adaptation of the pediatric patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
    Schroeder KM; Rizzieri T; Lion RR; Mtenga N; Gisiri M; McFatrich M; Reeve BB
    J Patient Rep Outcomes; 2023 Jun; 7(1):56. PubMed ID: 37306774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).
    Hagelstein V; Ortland I; Wilmer A; Mitchell SA; Jaehde U
    Ann Oncol; 2016 Dec; 27(12):2294-2299. PubMed ID: 27681863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translation Into Simplified Chinese and Cultural Validation of the Pediatric Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events Using Cognitive Interviewing.
    Shen N; Ruan H; Sun J; Li Y; He M; Yuan C; Chang L
    Cancer Nurs; 2023 Jan-Feb 01; 46(1):E31-E40. PubMed ID: 35583994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Chung AE; Shoenbill K; Mitchell SA; Dueck AC; Schrag D; Bruner DW; Minasian LM; St Germain D; O'Mara AM; Baumgartner P; Rogak LJ; Abernethy AP; Griffin AC; Basch EM
    J Am Med Inform Assoc; 2019 Apr; 26(4):276-285. PubMed ID: 30840079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
    Basch E; Reeve BB; Mitchell SA; Clauser SB; Minasian LM; Dueck AC; Mendoza TR; Hay J; Atkinson TM; Abernethy AP; Bruner DW; Cleeland CS; Sloan JA; Chilukuri R; Baumgartner P; Denicoff A; St Germain D; O'Mara AM; Chen A; Kelaghan J; Bennett AV; Sit L; Rogak L; Barz A; Paul DB; Schrag D
    J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25265940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive Interview-Based Validation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Adolescents with Cancer.
    Reeve BB; McFatrich M; Pinheiro LC; Freyer DR; Basch EM; Baker JN; Withycombe JS; Sung L; Mack JW; Waldron MK; Mowbray C; Palma D; Hinds PS
    J Pain Symptom Manage; 2017 Apr; 53(4):759-766. PubMed ID: 28062347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linguistic and content validation of a German-language PRO-CTCAE-based patient-reported outcomes instrument to evaluate the late effect symptom experience after allogeneic hematopoietic stem cell transplantation.
    Kirsch M; Mitchell SA; Dobbels F; Stussi G; Basch E; Halter JP; De Geest S
    Eur J Oncol Nurs; 2015 Feb; 19(1):66-74. PubMed ID: 25190633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Bruner DW; Hanisch LJ; Reeve BB; Trotti AM; Schrag D; Sit L; Mendoza TR; Minasian L; O'Mara A; Denicoff AM; Rowland JH; Montello M; Geoghegan C; Abernethy AP; Clauser SB; Castro K; Mitchell SA; Burke L; Trentacosti AM; Basch EM
    Transl Behav Med; 2011 Mar; 1(1):110-22. PubMed ID: 24073038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LUTS patient reported outcomes tool: linguistic validation in 10 European languages.
    Brandt BA; Angün Ç; Coyne KS; Doshi S; Bavendam T; Kopp ZS
    Neurourol Urodyn; 2013 Jan; 32(1):75-81. PubMed ID: 22674460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors.
    Knoerl R; Mazzola E; Mitchell SA; Hong F; Salehi E; McCleary N; Ligibel JA; Reyes K; Berry DL
    J Patient Rep Outcomes; 2021 Sep; 5(1):101. PubMed ID: 34568984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag.
    Davis S; Edwards T; Norcross L; Fehnel S; Beaudet A; Eckart M; Fastenau J
    J Patient Rep Outcomes; 2023 Dec; 7(1):134. PubMed ID: 38108945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.